These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 30709811)

  • 1. Clinical and microbiological characteristics of Moraxella keratitis.
    McSwiney TJ; Knowles SJ; Murphy CC
    Br J Ophthalmol; 2019 Dec; 103(12):1704-1709. PubMed ID: 30709811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Moraxella keratitis: epidemiology and outcomes.
    Hoarau G; Merabet L; Brignole-Baudouin F; Mizrahi A; Borderie V; Bouheraoua N
    Eur J Clin Microbiol Infect Dis; 2020 Dec; 39(12):2317-2325. PubMed ID: 32648113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Moraxella species: infectious microbes identified by use of time-of-flight mass spectrometry.
    Takahashi S; Murata K; Ozawa K; Yamada H; Kawakami H; Nakayama A; Asano Y; Mochizuki K; Mikamo H
    Jpn J Ophthalmol; 2019 Jul; 63(4):328-336. PubMed ID: 31273564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Moraxella keratitis: predisposing factors and clinical review of 95 cases.
    Das S; Constantinou M; Daniell M; Taylor HR
    Br J Ophthalmol; 2006 Oct; 90(10):1236-8. PubMed ID: 16825274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment outcome of Moraxella keratitis: our experience with 18 cases--a retrospective review.
    Garg P; Mathur U; Athmanathan S; Rao GN
    Cornea; 1999 Mar; 18(2):176-81. PubMed ID: 10090363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Moraxella Keratitis: Analysis of Risk Factors, Clinical Characteristics, Management, and Treatment Outcomes.
    Durrani AF; Faith SC; Kowalski RP; Yu M; Romanowski E; Shanks R; Dhaliwal D; Jhanji V
    Am J Ophthalmol; 2019 Jan; 197():17-22. PubMed ID: 30201340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Characteristics and Bacteriological Profile of Moraxella Keratitis.
    Inoue H; Suzuki T; Inoue T; Hattori T; Nejima R; Todokoro D; Hoshi S; Eguchi H; Miyamoto H; Ohashi Y
    Cornea; 2015 Sep; 34(9):1105-9. PubMed ID: 25970435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Characteristics and Outcomes of Moraxella Keratitis.
    Zafar H; Tan SZ; Walkden A; Fullwood C; Au L; Brahma A; Carley F
    Cornea; 2018 Dec; 37(12):1551-1554. PubMed ID: 30222715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extensively and pan-drug resistant Pseudomonas aeruginosa keratitis: clinical features, risk factors, and outcome.
    Fernandes M; Vira D; Medikonda R; Kumar N
    Graefes Arch Clin Exp Ophthalmol; 2016 Feb; 254(2):315-22. PubMed ID: 26537122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Characteristics of 17 Patients with Moraxella Keratitis.
    Tobimatsu Y; Inada N; Shoji J; Yamagami S
    Semin Ophthalmol; 2018; 33(5):726-732. PubMed ID: 29308970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Moraxella keratitis: risk factors, presentation, and management.
    Mian SI; Malta JB
    Acta Ophthalmol; 2011 Mar; 89(2):e208-9. PubMed ID: 19930213
    [No Abstract]   [Full Text] [Related]  

  • 12. Bacterial keratitis in a tertiary eye centre in Iran: a retrospective study.
    Rahimi F; Hashemian MN; Khosravi A; Moradi G; Bamdad S
    Middle East Afr J Ophthalmol; 2015; 22(2):238-44. PubMed ID: 25949085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors, microbiological findings, and clinical outcomes in cases of microbial keratitis admitted to a tertiary referral center in ireland.
    Saeed A; D'Arcy F; Stack J; Collum LM; Power W; Beatty S
    Cornea; 2009 Apr; 28(3):285-92. PubMed ID: 19387229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multidrug-Resistant Pseudomonas aeruginosa Keratitis: Risk Factors, Clinical Characteristics, and Outcomes.
    Vazirani J; Wurity S; Ali MH
    Ophthalmology; 2015 Oct; 122(10):2110-4. PubMed ID: 26189185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bacterial keratitis due to Moraxella nonliquefaciens.
    Díaz Barrón A; Sanz Gallen L; Hervás Hernandis JM; Tarragó Simón E; Duch-Samper AM
    Arch Soc Esp Oftalmol (Engl Ed); 2020 Jul; 95(7):357-360. PubMed ID: 32241585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microbial Keratitis in Thyroid Eye Disease: Clinical Features, Microbiological Profile, and Treatment Outcome.
    Naik MN; Vasanthapuram VH; Joseph J; Murthy SI
    Ophthalmic Plast Reconstr Surg; 2019; 35(6):543-548. PubMed ID: 30844912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pediatric microbial keratitis: a tertiary hospital study.
    Song X; Xu L; Sun S; Zhao J; Xie L
    Eur J Ophthalmol; 2012; 22(2):136-41. PubMed ID: 21574163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors in microbial keratitis leading to penetrating keratoplasty.
    Miedziak AI; Miller MR; Rapuano CJ; Laibson PR; Cohen EJ
    Ophthalmology; 1999 Jun; 106(6):1166-70; discussion 1171. PubMed ID: 10366087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serratia corneal ulcers: a retrospective clinical study.
    Mah-Sadorra JH; Najjar DM; Rapuano CJ; Laibson PR; Cohen EJ
    Cornea; 2005 Oct; 24(7):793-800. PubMed ID: 16160494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteus mirabilis Keratitis: Risk Factors, Clinical Features, Treatment Outcomes, and Microbiological Characteristics.
    Mo S; Durrani AF; Safiullah Z; Kowalski RP; Jhanji V
    Cornea; 2021 Jun; 40(6):704-709. PubMed ID: 32833846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.